SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'C1L'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	TYR A 524 LEU A 635 LEU A 675 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) None C1L A 1 (-4.3A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.58A	1tbfA-3ui7A: 44.4	1tbfA-3ui7A: 38.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 10	TYR A 524 HIS A 525 ALA A 689 GLY A 728 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None None C1L A 1 (-3.5A)	1.27A	1uhoA-3ui7A: 41.3	1uhoA-3ui7A: 39.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 10	TYR A 524 HIS A 525 PHE A 696 GLN A 726 GLY A 728 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) None C1L A 1 (-3.5A)	0.44A	1uhoA-3ui7A: 41.3	1uhoA-3ui7A: 39.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 HIS A 567 LEU A 675 ILE A 692 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.91A	1xlxA-3ui7A: 38.0	1xlxA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 HIS A 567 ILE A 692 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.68A	1xlxB-3ui7A: 38.0	1xlxB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.19A	1xlxB-3ui7A: 38.0	1xlxB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 696 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-3.5A)	0.83A	1xmuA-3ui7A: 38.1	1xmuA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 696 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-3.5A)	1.49A	1xmuA-3ui7A: 38.1	1xmuA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 696	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A)	0.58A	1xmuB-3ui7A: 38.2	1xmuB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 696	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 ( 4.7A)	1.49A	1xmuB-3ui7A: 38.2	1xmuB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	8 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.89A	1xomA-3ui7A: 38.5	1xomA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-3.5A)	1.45A	1xomA-3ui7A: 38.5	1xomA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.26A	1xomA-3ui7A: 38.5	1xomA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-3.5A)	1.47A	1xomB-3ui7A: 38.5	1xomB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 LEU A 675 ILE A 692 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.93A	1xomB-3ui7A: 38.5	1xomB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.25A	1xomB-3ui7A: 38.5	1xomB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.5A)	0.87A	1xoqA-3ui7A: 38.6	1xoqA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-3.5A)	1.44A	1xoqA-3ui7A: 38.6	1xoqA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.5A)	0.90A	1xoqB-3ui7A: 38.5	1xoqB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-3.5A)	1.46A	1xoqB-3ui7A: 38.5	1xoqB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 ASP A 674 LEU A 675 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.19A	1xosA-3ui7A: 38.3	1xosA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.70A	1xosA-3ui7A: 38.3	1xosA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 LEU A 675 ILE A 692 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.65A	1xotA-3ui7A: 38.2	1xotA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.13A	1xotA-3ui7A: 38.2	1xotA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.04A	1xotB-3ui7A: 38.4	1xotB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2C7V_B_MTXB1272_1 (PTERIDINE REDUCTASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	SER A 677 PRO A 523 ASP A 674 MET A 714 GLU A 699	C1L A 1 (-3.6A) None ZN A 772 (-2.4A) None None	1.24A	2c7vB-3ui7A: undetectable	2c7vB-3ui7A: 20.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 11	TYR A 524 HIS A 525 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.47A	2h42A-3ui7A: 40.9	2h42A-3ui7A: 39.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 635 LEU A 675 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) None C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.47A	2h42C-3ui7A: 41.2	2h42C-3ui7A: 39.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_A_EV1A1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	12 / 12	TYR A 524 HIS A 525 LEU A 635 LEU A 675 VAL A 678 ILE A 692 TYR A 693 GLU A 695 PHE A 696 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-4.9A) C1L A 1 (-4.3A) None None C1L A 1 ( 4.7A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.54A	2weyA-3ui7A: 50.9	2weyA-3ui7A: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_B_EV1B1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	8 / 8	LEU A 635 VAL A 678 ILE A 692 TYR A 693 PHE A 696 MET A 713 GLN A 726 PHE A 729	None C1L A 1 (-4.9A) C1L A 1 (-4.3A) None C1L A 1 ( 4.7A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.45A	2weyB-3ui7A: 49.6	2weyB-3ui7A: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3B2R_A_VDNA1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 LEU A 675 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.69A	3b2rA-3ui7A: 36.5	3b2rA-3ui7A: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3B2R_B_VDNB1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 11	TYR A 524 HIS A 525 LEU A 675 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.54A	3b2rB-3ui7A: 36.2	3b2rB-3ui7A: 40.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_A_ROFA901_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	ASP A 674 LEU A 675 GLN A 726	ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-2.9A)	0.41A	3g4lA-3ui7A: 38.0	3g4lA-3ui7A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.5A)	0.83A	3g4lB-3ui7A: 38.2	3g4lB-3ui7A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_C_ROFC903_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A)	0.59A	3g4lC-3ui7A: 38.0	3g4lC-3ui7A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 GLN A 726	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-2.9A)	0.75A	3g4lD-3ui7A: 38.3	3g4lD-3ui7A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	TYR A 524 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.16A	3iakA-3ui7A: 37.8	3iakA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	TYR A 524 ILE A 692 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.74A	3iakA-3ui7A: 37.8	3iakA-3ui7A: 28.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 9	TYR A 524 HIS A 525 LEU A 635 MET A 713 GLN A 726 PHE A 729 VAL A 733	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A) None	0.60A	3jwqA-3ui7A: 44.3	3jwqA-3ui7A: 42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 11	TYR A 524 HIS A 525 LEU A 635 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.77A	3jwqB-3ui7A: 44.0 3jwqC-3ui7A: 44.0	3jwqB-3ui7A: 42.11 3jwqC-3ui7A: 42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 7	TYR A 524 HIS A 525 MET A 713 GLN A 726 PHE A 729 VAL A 733	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A) None	0.57A	3jwqC-3ui7A: 44.0	3jwqC-3ui7A: 42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 11	TYR A 524 HIS A 525 LEU A 635 PHE A 696 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 ( 4.7A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.69A	3jwqA-3ui7A: 44.3 3jwqD-3ui7A: 43.8	3jwqA-3ui7A: 42.11 3jwqD-3ui7A: 42.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 9	TYR A 524 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.04A	3tvxA-3ui7A: 38.5	3tvxA-3ui7A: 28.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 7	TYR A 524 ILE A 692 PHE A 696 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.03A	3tvxB-3ui7A: 38.3	3tvxB-3ui7A: 28.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OEX_A_CUA604_0 (THIOCYANATE DEHYDROGENASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	HIS A 529 HIS A 525 HIS A 567	ZN A 772 (-3.5A) C1L A 1 (-4.1A) None	1.01A	5oexA-3ui7A: undetectable	5oexA-3ui7A: 19.71

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1TBF_A_VIAA501_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;LEU A 635;LEU A 675;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);None;C1L A   1 (-4.3A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.58A","1tbfA-3ui7A:44.4",null],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;ALA A 689;GLY A 728;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;None;C1L A   1 (-3.5A)","1.27A","1uhoA-3ui7A:41.3","1tbfA-3ui7A:38.53"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;PHE A 696;GLN A 726;GLY A 728;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);None;C1L A   1 (-3.5A)","0.44A","1uhoA-3ui7A:41.3","1uhoA-3ui7A:39.23"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;HIS A 567;LEU A 675;ILE A 692;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.91A","1xlxA-3ui7A:38.0","1uhoA-3ui7A:39.23"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;HIS A 567;ILE A 692;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.68A","1xlxB-3ui7A:38.0","1xlxA-3ui7A:27.10"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.19A","1xlxB-3ui7A:38.0","1xlxB-3ui7A:27.10"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 696;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-3.5A)","0.83A","1xmuA-3ui7A:38.1","1xlxB-3ui7A:27.10"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 696;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-3.5A)","1.49A","1xmuA-3ui7A:38.1","1xmuA-3ui7A:27.10"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 696","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A)","0.58A","1xmuB-3ui7A:38.2","1xmuA-3ui7A:27.10"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 696","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 ( 4.7A)","1.49A","1xmuB-3ui7A:38.2","1xmuB-3ui7A:27.10"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",8,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.89A","1xomA-3ui7A:38.5","1xmuB-3ui7A:27.10"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-3.5A)","1.45A","1xomA-3ui7A:38.5","1xomA-3ui7A:28.53"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.26A","1xomA-3ui7A:38.5","1xomA-3ui7A:28.53"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-3.5A)","1.47A","1xomB-3ui7A:38.5","1xomA-3ui7A:28.53"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;LEU A 675;ILE A 692;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.93A","1xomB-3ui7A:38.5","1xomB-3ui7A:28.53"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.25A","1xomB-3ui7A:38.5","1xomB-3ui7A:28.53"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.5A)","0.87A","1xoqA-3ui7A:38.6","1xomB-3ui7A:28.53"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-3.5A)","1.44A","1xoqA-3ui7A:38.6","1xoqA-3ui7A:28.53"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.5A)","0.90A","1xoqB-3ui7A:38.5","1xoqA-3ui7A:28.53"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-3.5A)","1.46A","1xoqB-3ui7A:38.5","1xoqB-3ui7A:28.53"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;ASP A 674;LEU A 675;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.19A","1xosA-3ui7A:38.3","1xoqB-3ui7A:28.53"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.70A","1xosA-3ui7A:38.3","1xosA-3ui7A:27.10"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;LEU A 675;ILE A 692;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.65A","1xotA-3ui7A:38.2","1xosA-3ui7A:27.10"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.13A","1xotA-3ui7A:38.2","1xotA-3ui7A:27.10"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.04A","1xotB-3ui7A:38.4","1xotA-3ui7A:27.10"],["2C7V_B_MTXB1272_1","PTERIDINE REDUCTASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"SER A 677;PRO A 523;ASP A 674;MET A 714;GLU A 699","C1L A   1 (-3.6A);None; ZN A 772 (-2.4A);None;None","1.24A","2c7vB-3ui7A:undetectable","1xotB-3ui7A:27.10"],["2H42_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.47A","2h42A-3ui7A:40.9","2c7vB-3ui7A:20.52"],["2H42_C_VIAC903_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 635;LEU A 675;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);None;C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.47A","2h42C-3ui7A:41.2","2h42A-3ui7A:39.77"],["2WEY_A_EV1A1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",12,"TYR A 524;HIS A 525;LEU A 635;LEU A 675;VAL A 678;ILE A 692;TYR A 693;GLU A 695;PHE A 696;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-4.9A);C1L A   1 (-4.3A);None;None;C1L A   1 ( 4.7A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.54A","2weyA-3ui7A:50.9","2h42C-3ui7A:39.77"],["2WEY_B_EV1B1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",8,"LEU A 635;VAL A 678;ILE A 692;TYR A 693;PHE A 696;MET A 713;GLN A 726;PHE A 729","None;C1L A   1 (-4.9A);C1L A   1 (-4.3A);None;C1L A   1 ( 4.7A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.45A","2weyB-3ui7A:49.6","2weyA-3ui7A:100.00"],["3B2R_A_VDNA1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;LEU A 675;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.69A","3b2rA-3ui7A:36.5","2weyB-3ui7A:100.00"],["3B2R_B_VDNB1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 675;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.54A","3b2rB-3ui7A:36.2","3b2rA-3ui7A:40.64"],["3G4L_A_ROFA901_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"ASP A 674;LEU A 675;GLN A 726"," ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-2.9A)","0.41A","3g4lA-3ui7A:38.0","3b2rB-3ui7A:40.64"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.5A)","0.83A","3g4lB-3ui7A:38.2","3g4lA-3ui7A:27.92"],["3G4L_C_ROFC903_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A)","0.59A","3g4lC-3ui7A:38.0","3g4lB-3ui7A:27.92"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;GLN A 726","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-2.9A)","0.75A","3g4lD-3ui7A:38.3","3g4lC-3ui7A:27.92"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.16A","3iakA-3ui7A:37.8","3g4lD-3ui7A:27.92"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;ILE A 692;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.74A","3iakA-3ui7A:37.8","3iakA-3ui7A:28.53"],["3JWQ_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;LEU A 635;MET A 713;GLN A 726;PHE A 729;VAL A 733","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A);None","0.60A","3jwqA-3ui7A:44.3","3iakA-3ui7A:28.53"],["3JWQ_B_VIAB901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;LEU A 635;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.77A","3jwqB-3ui7A:44.0;3jwqC-3ui7A:44.0","3jwqA-3ui7A:42.11"],["3JWQ_C_VIAC901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;MET A 713;GLN A 726;PHE A 729;VAL A 733","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A);None","0.57A","3jwqC-3ui7A:44.0","3jwqB-3ui7A:42.11;3jwqC-3ui7A:42.11"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;LEU A 635;PHE A 696;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 ( 4.7A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.69A","3jwqA-3ui7A:44.3;3jwqD-3ui7A:43.8","3jwqC-3ui7A:42.11"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.04A","3tvxA-3ui7A:38.5","3jwqA-3ui7A:42.11;3jwqD-3ui7A:42.11"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;ILE A 692;PHE A 696;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.03A","3tvxB-3ui7A:38.3","3tvxA-3ui7A:28.73"],["5OEX_A_CUA604_0","THIOCYANATE DEHYDROGENASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"HIS A 529;HIS A 525;HIS A 567"," ZN A 772 (-3.5A);C1L A   1 (-4.1A);None","1.01A","5oexA-3ui7A:undetectable","3tvxB-3ui7A:28.73"]]